ArticleAntioxidants (Basel, Switzerland)2024
Efficacy of Omega-5 NanoPSO Treatment in the Hippocampus, Through Antioxidant Mechanisms, After an Ischemia/Reperfusion Injury, in Murine Model.
Article in Antioxidants (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Stroke is the third cause of death worldwide and a health problem, and current therapy continues to be very poor. It promotes an alteration associated with excitotoxicity, oxidative stress, and inflammatory processes, exacerbating the damage in the brain. Although cortical areas are the most affected by stroke, the hippocampus can be impacted in the long term through the pathways it connects with these areas, which are associated further with motor alterations; this encourages the search for new therapeutic approaches. Omega-5, being an antioxidant, participates in regulating oxidative stress. A recently designed nanoemulsified compound coupled with pomegranate seed oil (NanoPSO) maintains bioavailability in the body for longer. Omega-5 NanoPSO is more effective in different models of neurodegenerative diseases and metabolic disorders. Therefore, it is important to analyze the effect of omega-5 NanoPSO on ischemic damage through changes in the hippocampus, oxidative mechanisms, and behavioral outcomes. Male Wistar rats were used in five groups; three groups were subjected to an ischemic event through bilateral occlusion of the carotid arteries. An ischemia group received omega-5 NanoPSO after injury, and another group received omega-5 NanoPSO performed two weeks before the ischemic event and three weeks after the surgical process. The control and sham groups did not show changes in the hippocampus and behavior. In the ischemia group, neuronal loss, oxidative stress, and a higher expression of astrocytes were maintained in the hippocampal region, and behavior was modified. In the post and pre-treatment group with omega-5 NanoPSO, we observed reduced damage, glial proliferation, and oxidative stress. It increased neuron survival in the hippocampal region and improved the locomotion. These results highlight its promise for use in clinical settings to treat patients suffering from ischemic brain injury.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.